Strides Pharma Science Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Strides Pharma Science de 24.4% y 16.9% por año respectivamente. Se prevé que el BPA crezca en un 24.4% al año. Se espera que la rentabilidad financiera sea de 21.8% en 3 años.
Información clave
24.4%
Tasa de crecimiento de los beneficios
24.39%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 16.1% |
| Tasa de crecimiento de los ingresos | 16.9% |
| Rentabilidad financiera futura | 21.75% |
| Cobertura de analistas | Low |
| Última actualización | 15 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 16
STAR: Upcoming Results And Dividend Decision Will Guide Balanced Outlook
Analysts have reiterated their ₹1,119 price target on Strides Pharma Science, citing only minor adjustments to revenue growth, profit margin and future P/E assumptions that support maintaining the existing valuation view. What’s in the News for Strides Pharma Science A Board of Directors meeting is scheduled for May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (source: company board meeting disclosure).Actualización de narrativa • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Actualización de narrativa • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
Actualización de narrativa • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.Actualización de narrativa • Apr 13
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).Actualización de narrativa • Mar 30
STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Actualización de narrativa • Mar 16
STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Actualización de narrativa • Sep 05
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
Nueva narrativa • Feb 10
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.Artículo de análisis • Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...Artículo de análisis • Oct 21
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Artículo de análisis • Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Artículo de análisis • Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...Artículo de análisis • Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...Artículo de análisis • Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...Artículo de análisis • Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2028 | 68,263 | 8,943 | 6,565 | 9,473 | 2 |
| 3/31/2027 | 58,080 | 6,266 | 4,805 | 7,305 | 2 |
| 3/31/2026 | 48,587 | 5,562 | 2,846 | 7,025 | N/A |
| 12/31/2025 | 47,256 | 5,114 | N/A | N/A | N/A |
| 9/30/2025 | 46,846 | 3,973 | 3,989 | 6,960 | N/A |
| 6/30/2025 | 46,307 | 3,416 | N/A | N/A | N/A |
| 3/31/2025 | 45,653 | 4,053 | 4,419 | 6,844 | N/A |
| 12/31/2024 | 45,794 | 3,424 | N/A | N/A | N/A |
| 9/30/2024 | 44,103 | 1,771 | 6,344 | 8,172 | N/A |
| 6/30/2024 | 42,086 | -475 | N/A | N/A | N/A |
| 3/31/2024 | 38,901 | -1,202 | 5,829 | 7,011 | N/A |
| 12/31/2023 | 39,535 | -1,525 | N/A | N/A | N/A |
| 9/30/2023 | 37,806 | -2,280 | 3,043 | 3,903 | N/A |
| 6/30/2023 | 36,783 | -924 | N/A | N/A | N/A |
| 3/31/2023 | 36,884 | -2,212 | -505 | 444 | N/A |
| 12/31/2022 | 35,680 | -1,824 | N/A | N/A | N/A |
| 9/30/2022 | 34,976 | -2,241 | -2,101 | -1,144 | N/A |
| 6/30/2022 | 33,220 | -3,909 | N/A | N/A | N/A |
| 3/31/2022 | 30,703 | -4,602 | -4,012 | -2,578 | N/A |
| 12/31/2021 | 31,127 | -4,425 | N/A | N/A | N/A |
| 9/30/2021 | 31,504 | -2,830 | -1,188 | 1,572 | N/A |
| 6/30/2021 | 32,224 | -543 | N/A | N/A | N/A |
| 3/31/2021 | 33,159 | 2,545 | 1,840 | 4,814 | N/A |
| 12/31/2020 | 30,260 | 28 | N/A | N/A | N/A |
| 9/30/2020 | 29,264 | 589 | 970 | 2,699 | N/A |
| 6/30/2020 | 28,480 | 1,266 | N/A | N/A | N/A |
| 3/31/2020 | 27,520 | 492 | 548 | 2,048 | N/A |
| 12/31/2019 | 35,828 | 2,859 | N/A | N/A | N/A |
| 9/30/2019 | 34,203 | 2,169 | N/A | 1,896 | N/A |
| 6/30/2019 | 32,248 | 745 | N/A | N/A | N/A |
| 3/31/2019 | 21,784 | 840 | N/A | 601 | N/A |
| 12/31/2018 | 28,547 | -93 | N/A | N/A | N/A |
| 9/30/2018 | 28,090 | 139 | N/A | N/A | N/A |
| 6/30/2018 | 28,451 | 415 | N/A | N/A | N/A |
| 3/31/2018 | 28,451 | 544 | N/A | 1,871 | N/A |
| 12/31/2017 | 35,810 | 1,050 | N/A | N/A | N/A |
| 9/30/2017 | 36,593 | 1,124 | N/A | N/A | N/A |
| 6/30/2017 | 35,357 | 1,712 | N/A | N/A | N/A |
| 3/31/2017 | 27,554 | 2,335 | N/A | 2,881 | N/A |
| 12/31/2016 | 37,237 | 2,840 | N/A | N/A | N/A |
| 9/30/2016 | 36,573 | 2,410 | N/A | N/A | N/A |
| 6/30/2016 | 34,189 | 2,168 | N/A | N/A | N/A |
| 3/31/2016 | 28,622 | 1,317 | N/A | 732 | N/A |
| 12/31/2015 | 24,901 | 1,152 | N/A | N/A | N/A |
| 9/30/2015 | 12,962 | 860 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (24.4% al año) de STAR es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (24.4% al año) de STAR crezcan más rápidamente que el mercado Indian (16.2% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de STAR crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (16.9% al año) de STAR crezcan más rápidamente que los del mercado Indian (10.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 16.9% al año) de STAR crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de STAR sea alta dentro de 3 años (21.8%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/30 14:13 |
| Precio de las acciones al final del día | 2026/06/30 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Strides Pharma Science Limited está cubierta por 15 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |